Multiple Sclerosis

 

Advanced Search

Journal Navigation

Journal Home

Subscriptions

Archive

Contact Us

Table of Contents

Click here for more information

Sign In to gain access to subscriptions and/or personal tools.
This Article
Right arrow Abstract Freely available
Right arrow Free Full Text (Free PDF) Free
Right arrow Alert me when this article is cited
Right arrow Alert me if a correction is posted
Right arrow Citation Map
Services
Right arrow Email this article to a friend
Right arrow Similar articles in this journal
Right arrow Similar articles in ISI Web of Science
Right arrow Similar articles in PubMed
Right arrow Alert me to new issues of the journal
Right arrow Add to Saved Citations
Right arrow Download to citation manager
Right arrowRequest Permissions
Right arrow Request Reprints
Right arrow Add to My Marked Citations
Citing Articles
Right arrow Citing Articles via ISI Web of Science (2)
Right arrow Citing Articles via Google Scholar
Google Scholar
Right arrow Articles by Gran, B
Right arrow Articles by Rostami, A M
Right arrow Search for Related Content
PubMed
Right arrow PubMed Citation
Right arrow Articles by Gran, B
Right arrow Articles by Rostami, A M
Social Bookmarking
Add to CiteULike   Add to Connotea   Add to Del.icio.us   Add to Digg   Add to Reddit   Add to Technorati  
What's this?
Multiple Sclerosis, Vol. 12, No. 6, 688-697 (2006)
DOI: 10.1177/1352458506070769
© 2006 SAGE Publications

The protease inhibitor, Bowman-Birk Inhibitor, suppresses experimental autoimmune encephalomyelitis: a potential oral therapy for multiple sclerosis

B Gran

Department of Neurology, Thomas Jefferson University, Philadelphia, PA, USA, Division of Clinical Neurology, University of Nottingham Medical School, Queen’s Medical Centre, Nottingham, UK, bruno.gran{at}nottingham.ac.uk

N Tabibzadeh

Department of Neurology, Thomas Jefferson University, Philadelphia, PA, USA

A Martin

Department of Neurology, Thomas Jefferson University, Philadelphia, PA, USA

E S Ventura

Department of Neurology, Thomas Jefferson University, Philadelphia, PA, USA

J H Ware

Department of Radiation Oncology, University of Pennsylvania, Philadelphia, PA, USA

G-X Zhang

Department of Neurology, Thomas Jefferson University, Philadelphia, PA, USA

J L Parr

Department of Pathology and Laboratory Medicine, University of Pennsylvania, Philadelphia, PA, USA

A R Kennedy

Department of Radiation Oncology, University of Pennsylvania, Philadelphia, PA, USA

A M Rostami

Department of Neurology, Thomas Jefferson University, Philadelphia, PA, USA, a.m.rostami{at}jefferson.edu

Available treatments for multiple sclerosis (MS) require frequent injections and have significant side effects. Proteases generated during inflammation are involved in the induction of tissue damage during inflammatory demyelination in the central nervous system (CNS). The Bowman-Birk Inhibitor (BBI), a soy-derived protease inhibitor with anti-carcinogenic and anti-inflammatory properties, has been shown to be well tolerated in clinical trials for pre-cancerous conditions, such as oral leukoplakia and the inflammatory disease, ulcerative colitis. We hypothesized that BBI may modulate experimental autoimmune encephalomyelitis (EAE), an animal model of MS. The BBI concentrate (BBIC), a soybean extract enriched in BBI, was administered to myelin basic protein (MBP)-immunized Lewis rats by gastric gavage in different treatment regimens, during the induction or the effector phase of disease. BBIC significantly delayed disease onset and suppressed disease severity, clinically and pathologically, in all treatment protocols. Both in vitro and ex vivo, BBIC inhibited MBP-specific proliferation of lymph node cells. BBIC reduced the activity of matrix metalloproteinase (MMP)-2 and -9 in spleen cell supernatants and was detected in the CNS of treated rats. BBIC suppresses EAE, it can be administered orally, and it is safe and relatively inexpensive. It may have a therapeutic role in patients with MS.

Key Words: experimental autoimmune encephalomyelitis • immunology • matrix metalloproteinase • multiple sclerosis • protease inhibitor • therapies

References

  • Bayas A, Gold R. Lessons from 10 years of interferon beta-1b (Betaferon/Betaseron) treatment . J Neurol 2003; 250: IV3-IV8 .[Medline] [Order article via Infotrieve]
  • Edgar CM, Brunet DG, Fenton P, McBride EV, Green P. Lipoatrophy in patients with multiple sclerosis on glatiramer acetate . Can J Neurol Sci 2004; 31: 58-63 .[ISI][Medline] [Order article via Infotrieve]
  • Neuhaus O, Stuve O, Zamvil SS, Hartung HP. Are statins a treatment option for multiple sclerosis? Lancet Neurol 2004; 3: 369-371 .[CrossRef][ISI][Medline] [Order article via Infotrieve]
  • t’Hart BA, Amor S. The use of animal models to investigate the pathogenesis of neuroinflammatory disorders of the central nervous system . Curr Opin Neurol 2003; 16: 375-383 .[CrossRef][ISI][Medline] [Order article via Infotrieve]
  • Martin R, McFarland HF. Immunological aspects of experimental allergic encephalomyelitis and multiple sclerosis . Crit Rev Clin Lab Sci 1995; 32: 121-182 .[ISI][Medline] [Order article via Infotrieve]
  • Gran B, Rostami A. T cells, cytokines, and autoantigens in multiple sclerosis . Curr Neurol Neurosci Rep 2001; 1: 263-270 .[Medline] [Order article via Infotrieve]
  • Cuzner ML, Opdenakker G. Plasminogen activators and matrix metalloproteases, mediators of extracellular proteolysis in inflammatory demyelination of the central nervous system . J Neuroimmunol 1999; 94: 1-14 .[CrossRef][ISI][Medline] [Order article via Infotrieve]
  • Duncan ME, Richardson JP, Murray GI, Melvin WT, Fothergill JE. Human matrix metalloproteinase-9: activation by limited trypsin treatment and generation of monoclonal antibodies specific for the activated form . Eur J Biochem 1998; 258: 37-43 .[ISI][Medline] [Order article via Infotrieve]
  • Gijbels K, Proost P, Masure S, Carton H, Billiau A, Opdenakker G. Gelatinase B is present in the cerebrospinal fluid during experimental autoimmune encephalomyelitis and cleaves myelin basic protein . J Neurosci Res 1993; 36: 432-440 .[CrossRef][ISI][Medline] [Order article via Infotrieve]
  • Chandler S, Coates R, Gearing A, Lury J, Wells G, Bone E. Matrix metalloproteinases degrade myelin basic protein . Neurosci Lett 1995; 201: 223-226 .[CrossRef][ISI][Medline] [Order article via Infotrieve]
  • Leppert D, Lindberg RL, Kappos L, Leib SL. Matrix metalloproteinases: multifunctional effectors of inflammation in multiple sclerosis and bacterial meningitis . Brain Res Brain Res Rev 2001; 36: 249-257 .[CrossRef][Medline] [Order article via Infotrieve]
  • Gijbels K, Masure S, Carton H, Opdenakker G. Gelatinase in the cerebrospinal fluid of patients with multiple sclerosis and other inflammatory neurological disorders . J Neuroimmunol 1992; 41: 29-34 .[Medline] [Order article via Infotrieve]
  • Lee MA, Palace J, Stabler G, Ford J, Gearing A, Miller K. Serum gelatinase B, TIMP-1 and TIMP-2 levels in multiple sclerosis. A longitudinal clinical and MRI study . Brain 1999; 122: 191-197 .[Abstract/Free Full Text]
  • Clements JM, Cossins JA, Wells GM, Corkill DJ, Helfrich K, Wood LMet al. Matrix metalloproteinase expression during experimental autoimmune encephalomyelitis and effects of a combined matrix metalloproteinase and tumour necrosis factor-alpha inhibitor . J Neuroimmunol 1997; 74: 85-94 .[CrossRef][ISI][Medline] [Order article via Infotrieve]
  • Bar-Or A, Nuttall RK, Duddy M, Alter A, Kim HJ, Ifergan Iet al. Analyses of all matrix metalloproteinase members in leukocytes emphasize monocytes as major inflammatory mediators in multiple sclerosis . Brain 2003; 126: 2738-2749 .[Abstract/Free Full Text]
  • Hewson AK, Smith T, Leonard JP, Cuzner ML. Suppression of experimental allergic encephalomyelitis in the Lewis rat by the matrix metalloproteinase inhibitor Ro31-9790 . Inflamm Res 1995; 44: 345-349 .[CrossRef][ISI][Medline] [Order article via Infotrieve]
  • Kennedy AR. The status of human trials utilizing Bowman-Birk Inhibitor Concentrate from soybeans. In Sugano M ed. Soy in health and disease prevention. CRC Press LLC , 2005.
  • Kennedy AR. Chemopreventive agents: protease inhibitors . Pharmacol Ther 1998; 78: 167-209 .[CrossRef][ISI][Medline] [Order article via Infotrieve]
  • McBride JD, Leatherbarrow RJ. Synthetic peptide mimics of the Bowman-Birk inhibitor protein . Curr Med Chem 2001; 8: 909-917 .[ISI][Medline] [Order article via Infotrieve]
  • Kennedy AR, Szuhaj BF, Newberne PM, Billings PC. Preparation and production of a cancer chemopreventive agent, Bowman-Birk inhibitor concentrate . Nutr Cancer 1993; 19: 281-302 .[ISI][Medline] [Order article via Infotrieve]
  • Deibler GE, Martenson RE, Kies MW. Large scale preparation of myelin basic protein from central nervous tissue of several mammalian species . Prep Biochem 1972; 2: 139-165 .[ISI][Medline] [Order article via Infotrieve]
  • Hilliard B, Ventura ES, Rostami A. Effect of timing of intravenous administration of myelin basic protein on the induction of tolerance in experimental allergic encephalomyelitis . Mult Scler 1999; 5: 2-9 .[ISI][Medline] [Order article via Infotrieve]
  • van Den Hout R, Pouw M, Gruppen H, van’t Riet K. Inactivation kinetics study of the Kunitz soybean trypsin inhibitor and the Bowman-Birk inhibitor . J Agric Food Chem 1998; 46: 281-285 .[CrossRef][ISI][Medline] [Order article via Infotrieve]
  • Chevalier-Larsen ES, O’Brien CJ, Wang H, Jenkins SC, Holder L, Lieberman APet al. Castration restores function and neurofilament alterations of aged symptomatic males in a transgenic mouse model of spinal and bulbar muscular atrophy . J Neurosci 2004; 24: 4778-4786 .[Abstract/Free Full Text]
  • Yaffe MP, Schatz G. Two nuclear mutations that block mitochondrial protein import in yeast . Proc Natl Acad Sci USA 1984; 81: 4819-4823 .[Abstract/Free Full Text]
  • Wan XS, Koch CJ, Lord EM, Manzone H, Billings PC, Donahue JJet al. Monoclonal antibodies differentially reactive with native and reductively modified Bowman-Birk protease inhibitor . J Immunol Methods 1995; 180: 117-130 .[CrossRef][ISI][Medline] [Order article via Infotrieve]
  • Deryugina EI, Bourdon MA, Jungwirth K, Smith JW, Strongin AY. Functional activation of integrin alpha V beta 3 in tumor cells expressing membrane-type 1 matrix metalloproteinase . Int J Cancer 2000; 86: 15-23 .[CrossRef][ISI][Medline] [Order article via Infotrieve]
  • Baram D, Vaday GG, Salamon P, Drucker I, Hershkoviz R, Mekori YA. Human mast cells release metalloproteinase-9 on contact with activated T cells: juxtacrine regulation by TNF-alpha . J Immunol 2001; 167: 4008-4016 .[Abstract/Free Full Text]
  • Slavin AJ, Soos JM, Stuve O, Patarroyo JC, Weiner HL, Fontana Aet al. Requirement for endocytic antigen processing and influence of invariant chain and H-2M deficiencies in CNS autoimmunity . J Clin Invest 2001; 108: 1133-1139 .[CrossRef][ISI][Medline] [Order article via Infotrieve]
  • Accapezzato D, Nisini R, Paroli M, Bruno G, Bonino F, Houghton Met al. Generation of an MHC class II-restricted T cell epitope by extracellular processing of hepatitis delta antigen . J Immunol 1998; 160: 5262-5266 .[Abstract/Free Full Text]
  • Descamps FJ, Van den Steen PE, Nelissen I, Van Damme J, Opdenakker G. Remnant epitopes generate autoimmunity: from rheumatoid arthritis and multiple sclerosis to diabetes . Adv Exp Med Biol 2003; 535: 69-77 .[ISI][Medline] [Order article via Infotrieve]
  • Kieseier BC, Seifert T, Giovannoni G, Hartung HP. Matrix metalloproteinases in inflammatory demyelination: targets for treatment . Neurology 1999; 53: 20-25 .[Abstract/Free Full Text]
  • Rosenberg GA. Matrix metalloproteinases in neuroinflammation . Glia 2002; 39: 279-291 .[CrossRef][ISI][Medline] [Order article via Infotrieve]
  • Bawadi HA, Antunes TM, Shih F, Losso JN. In vitro inhibition of the activation of Pro-matrix metalloproteinase 1 (Pro-MMP-1) and Pro-matrix metalloproteinase 9 (Pro-MMP-9) by rice and soybean Bowman-Birk inhibitors . J Agric Food Chem 2004; 52: 4730-4736 .[CrossRef][ISI][Medline] [Order article via Infotrieve]
  • Losso JN, Munene CN, Bansode RR, Bawadi HA. Inhibition of matrix metalloproteinase-1 activity by the soybean Bowman-Birk inhibitor . Biotechnol Lett 2004; 26: 901-905 .[CrossRef][ISI][Medline] [Order article via Infotrieve]
  • Billings PC, St Clair WH, Maki PA, Kennedy AR. Distribution of the Bowman-Birk protease inhibitor in mice following oral administration . Cancer Lett 1992; 62: 191-197 .[CrossRef][ISI][Medline] [Order article via Infotrieve]
  • Yavelow J, Finlay TH, Kennedy AR, Troll W. Bowman-Birk soybean protease inhibitor as an anticarcinogen . Cancer Res 1983; 43: 2454s-2459s .[Medline] [Order article via Infotrieve]
  • Larionova NI, Gladysheva IP, Tikhonova TV, Kazanskaya NF. Inhibition of cathepsin G and human granulocyte elastase by multiple forms of Bowman-Birk type soybean inhibitor . Biokhimiia 1993; 58: 1437-1444 .[Medline] [Order article via Infotrieve]
  • Frenkel K, Chrzan K, Ryan CA, Wiesner R, Troll W. Chymotrypsin-specific protease inhibitors decrease H2O2 formation by activated human polymorphonuclear leukocytes . Carcinogenesis 1987; 8: 1207-1212 .[Abstract/Free Full Text]
  • Ware JH, Wan XS, Rubin H, Schechter NM, Kennedy AR. Soybean Bowman-Birk protease inhibitor is a highly effective inhibitor of human mast cell chymase . Arch Biochem Biophys 1997; 344: 133-138 .[CrossRef][ISI][Medline] [Order article via Infotrieve]
  • Tchougounova E, Lundequist A, Fajardo I, Winberg JO, Abrink M, Pejler G. A key role for mast cell chymase in the activation of pro-matrix metalloprotease-9 and pro-matrix metalloprotease-2 . J Biol Chem 2005; 280: 9291-9296 .[Abstract/Free Full Text]
  • Page JG, Heath JE, May RD, Martin JF. 13-week toxicity study of Bowman-Birk Inhibitor Concentrate (BBIC) in rats. Southern Research Institute , 1994. Report No: SRI-CBE-94-060-7482.
  • Serota DG. Six-month oral toxicity study in Bowman-Birk Inhibitor Concentrate (BBIC) in mice. MPI Research Inc ., 2000. Report No: 560-057.
  • Armstrong WB, Kennedy AR, Wan XS, Taylor TH, Nguyen QA, Jensen Jet al. Clinical modulation of oral leukoplakia and protease activity by Bowman-Birk inhibitor concentrate in a phase IIa chemoprevention trial . Clin Cancer Res 2000; 6: 4684-4691 .[Abstract/Free Full Text]
  • Malkowicz SB, McKenna WG, Vaughn DJ, Wan XS, Propert KJ, Rockwell Ket al. Effects of Bowman-Birk inhibitor concentrate (BBIC) in patients with benign prostatic hyperplasia . Prostate 2001; 48: 16-28 .[CrossRef][ISI][Medline] [Order article via Infotrieve]
  • Lichtenstein GR, Deren J, Katz S, Kennedy AR, Ware JH. The Bowman-Birk protease inhibitor: a novel therapy for patients with active ulcerative colitis . Gastroenterology 2002; 122: A60-A60 .[CrossRef]
  • Weinstock-Guttman B, Bakshi R. Combination therapy for multiple sclerosis: the treatment strategy of the future? CNS Drugs 2004; 18: 777-792 .[CrossRef][ISI][Medline] [Order article via Infotrieve]

Add to CiteULike CiteULike   Add to Connotea Connotea   Add to Del.icio.us Del.icio.us   Add to Digg Digg   Add to Reddit Reddit   Add to Technorati Technorati    What's this?



This Article
Right arrow Abstract Freely available
Right arrow Free Full Text (Free PDF) Free
Right arrow Alert me when this article is cited
Right arrow Alert me if a correction is posted
Right arrow Citation Map
Services
Right arrow Email this article to a friend
Right arrow Similar articles in this journal
Right arrow Similar articles in ISI Web of Science
Right arrow Similar articles in PubMed
Right arrow Alert me to new issues of the journal
Right arrow Add to Saved Citations
Right arrow Download to citation manager
Right arrowRequest Permissions
Right arrow Request Reprints
Right arrow Add to My Marked Citations
Citing Articles
Right arrow Citing Articles via ISI Web of Science (2)
Right arrow Citing Articles via Google Scholar
Google Scholar
Right arrow Articles by Gran, B
Right arrow Articles by Rostami, A M
Right arrow Search for Related Content
PubMed
Right arrow PubMed Citation
Right arrow Articles by Gran, B
Right arrow Articles by Rostami, A M
Social Bookmarking
Add to CiteULike   Add to Connotea   Add to Del.icio.us   Add to Digg   Add to Reddit   Add to Technorati  
What's this?